Aminoglycosides抗生素市場－2026-2031年預測

Aminoglycosides抗生素市場預計將從 2025 年的 16.19 億美元成長到 2031 年的 20.38 億美元，複合年成長率為 3.91%。

Aminoglycosides抗生素市場涵蓋了一類重要的抗生素，它們具有殺菌活性，用於治療由革蘭氏陽性菌和革蘭氏陰性菌引起的嚴重全身性性行為感染。感染疾病。

核心治療價值與臨床需求

Aminoglycosides抗生素，包括慶大霉素和Amikacin等藥物，因其強效且快速的殺菌活性而備受推崇。它們獨特的抗菌機制抑制細菌蛋白質合成，使其即使面對嚴重的細菌感染也有效。這項特性鞏固了它們在治療膿毒症、醫院獲得性肺炎、複雜性尿道感染以及某些分枝桿菌感染疾病（包括結核病）等嚴重中的基石地位。在臨床實踐中，它們常用於重症病例，或作為聯合治療的一部分，旨在對抗抗藥性並擴大抗菌頻譜，這凸顯了它們作為抗菌治療重要工具的地位。

主要市場成長促進因素

市場需求受到多種持續且相互關聯的全球健康挑戰的驅動。多重抗藥性細菌（MDR）感染疾病的日益普及是主要促進因素。隨著第一線抗生素抗藥性的蔓延，人們越來越依賴Aminoglycosides等二線藥物來治療多重抗藥性結核病（MDR-TB）和其他抗藥性革蘭氏陰性病菌感染。全球感染疾病率的上升進一步加劇了這一趨勢，維持了對有效抗生素療法的穩定需求。

同時，獸藥市場也正經歷顯著的擴張。牲畜、家禽和伴侶動物感染疾病的上升推動了飼料、飲用水和治療製劑中Aminoglycosides抗生素的需求。水產養殖業的興起進一步擴大了其應用範圍。在全球動物性蛋白質生產集約化的推動下，獸藥市場已成為整體市場規模中重要且快速成長的組成部分。

藥物遞送系統的進步是重要的成長動力，旨在緩解此類藥物的主要限制：潛在的腎毒性和耳毒性。研發重點在於新型製劑，包括緩釋系統、脂質體包覆和奈米顆粒遞送。這些創新旨在提高藥物標靶化、增強療效、減少給藥頻率並降低副作用風險，從而有望擴大此類抗生素的安全有效應用範圍。

主要市場細分和藥物趨勢

市場按應用領域和具體藥物進行細分。就治療領域而言，呼吸道感染疾病（尤其是抗藥性結核病）的治療構成了一個主要且穩定的收入來源，這主要歸因於全球疾病負擔沉重，尤其是在發展中地區。

在眾多藥物中，慶大霉素因其頻譜活性、可靠的臨床療效和成本效益而佔據主導地位。它在許多醫療機構（尤其是資源有限的機構）中被廣泛用作第一線藥物，確保了其持續的高需求。Amikacin在治療對其他Aminoglycosides抗藥性的感染疾病方面發揮著尤為重要的作用，因此在醫院治療複雜病例時必不可少。

區域和法規環境

由於感染疾病負擔沉重，包括多重抗藥性結核病的高發生率（需要使用二線Aminoglycosides藥物治療），亞太地區預計將成為一個主要且成長最快的市場。該地區龐大的人口規模、不斷完善的醫療基礎設施以及眾多原料藥和製劑生產商的存在，進一步鞏固了其在全球供需中的核心地位。

在全球範圍內，氨基糖苷類抗生素市場在嚴格且不斷發展的法規結構下運作。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等機構對Aminoglycosides抗生素的生產和分銷實施嚴格的安全、有效性和品質標準。此外，國際衛生機構的指南提倡抗菌藥物管理，並強調合理使用這些藥物，包括治療藥物監測和聯合治療，以維持其療效並最大限度地減少抗藥性的產生。

競爭格局與策略方向

競爭格局包括專注於抗感染藥物的成熟製藥公司以及學名藥生產商。策略重點分為兩部分：一部分著重於最佳化成熟、經濟有效的藥物（例如慶大霉素）的生產和供應，以滿足大眾市場需求；另一部分則更注重創新，投資於先進的製劑技術，以開發安全性更高的下一代Aminoglycosides藥物。此外，各公司也致力於現有藥物的生命週期管理策略，並探索聯合治療以增強治療效果。

未來市場趨勢

Aminoglycosides抗生素市場的未來發展軌跡將受到日益嚴重的抗菌素抗藥性和治療創新需求之間持續緊張關係的影響。儘管這類藥物面臨毒性方面的挑戰，但其對抗抗藥性病原體的無可取代的療效將繼續推動市場需求。持續的獸醫需求以及人類在應對多重抗藥性感染疾病（MDR感染疾病）方面的迫切需求也將支撐市場成長。

長期發展將取決於能夠顯著提高治療指數的先進給藥系統在臨床上的成功應用。此外，市場仍將密切關注全球抗菌藥物管理政策和監管壓力，以遏制在人類和動物健康領域不當使用抗菌藥物的行為。因此，Aminoglycosides抗生素市場是一個成熟但至關重要的領域，它正透過製劑科學和戰略應用來適應現代挑戰，以確保其在可預見的未來繼續在嚴重細菌感染疾病的治療中發揮作用。

本報告的主要優勢：

• 深入分析：獲得主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
• 競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略進入市場的機會。
• 市場促進因素與未來趨勢：探索推動市場的動態因素和關鍵趨勢，以及它們將如何塑造未來的市場發展。
• 可操作的建議：利用這些見解，在動態環境中做出策略決策，並開拓新的商機和收入來源。
• 受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

它是用來做什麼的？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

• 2021年至2025年的歷史數據和2026年至2031年的預測數據
• 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
• 競爭定位、策略和市場佔有率分析
• 按業務板塊和地區（包括國家）分類的收入和預測評估
• 公司概況（策略、產品、財務資訊、關鍵發展等）

目錄

第1章執行摘要

第2章 市場概覽

• 市場概覽
• 市場定義
• 調查範圍
• 市場區隔

第3章 商業情境

• 市場促進因素
• 市場限制
• 市場機遇
• 波特五力分析
• 產業價值鏈分析
• 政策與法規
• 策略建議

第4章 技術展望

第5章Aminoglycosides抗生素市場（依產品分類）

• 介紹
• 新黴素
• 妥布黴素
• 慶大霉素
• Amikacin
• Paromomycin
• 其他

第6章Aminoglycosides抗生素市場（依給藥途徑分類）

• 介紹
• 腸外給藥
• 乳房內給藥
• 局部用藥
• 口服

第7章Aminoglycosides抗生素市場（依應用領域分類）

• 介紹
• 獸醫
• 皮膚感染疾病
• 呼吸系統疾病
• 尿道感染及骨盆腔疾病
• 其他

第8章Aminoglycosides抗生素市場（按地區分類）

• 介紹
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 其他
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 印尼
  • 泰國
  • 其他

第9章 競爭格局與分析

• 主要企業和策略分析
• 市佔率分析
• 合併、收購、協議和合作
• 競爭對手儀錶板

第10章：公司簡介

• Shimadzu
• Ringbio
• Medscape
• Fera Science
• Sigma-Aldrich
• Cipla Limited
• Novartis AG
• Vega Pharma Ltd
• Insmed Corporation

第11章附錄

• 貨幣
• 先決條件
• 基準年和預測年時間表
• 相關人員的主要收益
• 調查方法
• 簡稱

Aminoglycosides Market is expected to increase at a 3.91% CAGR, growing from USD 1.619 billion in 2025 to USD 2.038 billion in 2031.

The aminoglycosides market encompasses a critical class of bactericidal antibiotics used to treat severe systemic infections caused by both gram-positive and gram-negative bacteria. Characterized by their concentration-dependent killing mechanism and efficacy against a broad spectrum of pathogens, these drugs remain essential agents in human and veterinary medicine, particularly for complicated and resistant infections.

Core Therapeutic Value and Clinical Imperative

Aminoglycosides, which include agents such as gentamicin and amikacin, are valued for their potent, rapid bactericidal activity. Their unique mechanism of action disrupts bacterial protein synthesis, making them effective even against large bacterial inocula. This profile solidifies their role as a cornerstone in the treatment of serious conditions including sepsis, hospital-acquired pneumonia, complicated urinary tract infections, and certain mycobacterial infections, notably tuberculosis. Their clinical use is often reserved for severe cases or as part of combination therapies to combat resistance and broaden antimicrobial coverage, underscoring their position as a vital tool in the antimicrobial armamentarium.

Primary Market Growth Drivers

Market demand is sustained by several persistent and interrelated global health challenges. The escalating prevalence of multi-drug resistant (MDR) bacterial infections is a paramount driver. As resistance to first-line antibiotics spreads, the reliance on second-line agents like aminoglycosides for treating MDR tuberculosis and other resistant gram-negative infections increases. This trend is compounded by the growing global incidence of infectious diseases, which maintains a steady baseline demand for effective antibiotic therapies.

Simultaneously, the market is experiencing significant expansion within veterinary medicine. The rising incidence of infectious disease outbreaks in livestock, poultry, and companion animals drives the consumption of aminoglycosides in feed, water, and therapeutic formulations. Their use in aquaculture further broadens the application base. This veterinary segment represents a substantial and growing component of overall market volume, supported by the intensification of global animal protein production.

Advancements in drug delivery systems present a significant growth vector aimed at mitigating the class's primary limitations: potential nephrotoxicity and ototoxicity. Research and development are focused on novel formulations, including sustained-release systems, liposomal encapsulation, and nanoparticle-based delivery. These innovations are designed to improve drug targeting, enhance efficacy, reduce dosing frequency, and lower the risk of adverse effects, thereby potentially expanding the safe and effective use of these antibiotics.

Key Market Segments and Agent Dynamics

The market is segmented by both application and specific agent. In terms of therapeutic area, the treatment of respiratory infections, particularly drug-resistant tuberculosis, represents a major and consistent revenue segment due to the high global burden of the disease, especially in developing regions.

Among individual agents, gentamicin maintains a dominant position due to its broad-spectrum efficacy, established clinical history, and cost-effectiveness. Its widespread use as a first-line agent in many healthcare settings, especially where resources are constrained, ensures continued high-volume demand. Amikacin is particularly significant for its role in treating infections resistant to other aminoglycosides, making it crucial in hospital settings for complex cases.

Geographic Landscape and Regulatory Environment

The Asia-Pacific region is projected to be the dominant and fastest-growing market. This is driven by a high burden of infectious diseases, including a significant prevalence of multi-drug resistant tuberculosis, which necessitates treatment with second-line aminoglycosides. The region's large population base, expanding healthcare infrastructure, and the presence of major manufacturing entities for both active pharmaceutical ingredients and finished formulations further consolidate its central role in global supply and consumption.

The market operates within a stringent and evolving regulatory framework globally. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) enforce rigorous standards for the safety, efficacy, and quality of aminoglycoside production and distribution. Furthermore, guidelines from global health bodies promote antimicrobial stewardship, emphasizing the appropriate use of these agents-including therapeutic drug monitoring and combination therapy-to preserve their efficacy and minimize the development of resistance.

Competitive Landscape and Strategic Direction

The competitive environment includes established pharmaceutical companies specializing in anti-infectives and generic drug manufacturers. Strategic focus is bifurcated: one axis involves optimizing the production and supply of established, cost-effective agents like gentamicin for high-volume markets. The other, more innovation-focused axis involves investing in advanced formulation technologies to develop next-generation aminoglycoside products with improved safety profiles. Additionally, companies are engaged in lifecycle management strategies for existing drugs and exploring combination therapies to enhance therapeutic outcomes.

Future Market Trajectory

The future trajectory of the aminoglycosides market will be shaped by the persistent tension between rising antimicrobial resistance and the need for therapeutic innovation. While the class faces toxicity challenges, its irreplaceable efficacy against resistant pathogens ensures its continued necessity. Growth will be sustained by the ongoing veterinary demand and the critical human health need in managing MDR infections.

Long-term evolution depends on the successful clinical translation of advanced delivery systems that can demonstrably improve the therapeutic index. Furthermore, the market will remain sensitive to global antimicrobial stewardship policies and regulatory pressures aimed at curbing inappropriate use in both human and animal health. The aminoglycosides market, therefore, represents a mature but essential segment that is adapting to contemporary challenges through formulation science and strategic application, ensuring its role in managing serious bacterial infections for the foreseeable future.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Aminoglycosides Market Segmentation

• By Product
• Neomycin
• Tobramycin
• Gentamicin
• Amikacin
• Paromomycin
• Others
• By Route of Administration
• Parenteral
• Intra-mammary
• Topical
• Oral
• By Application
• Veterinary
• Skin Infection
• Respiratory Diseases
• UTI and Pelvic Diseases
• Others
• By Geography
• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. AMINOGLYCOSIDES MARKET BY PRODUCT

• 5.1. Introduction
• 5.2. Neomycin
• 5.3. Tobramycin
• 5.4. Gentamicin
• 5.5. Amikacin
• 5.6. Paromomycin
• 5.7. Others

6. AMINOGLYCOSIDES MARKET BY ROUTE OF ADMINISTRATION

• 6.1. Introduction
• 6.2. Parenteral
• 6.3. Intra-mammary
• 6.4. Topical
• 6.5. Oral

7. AMINOGLYCOSIDES MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Veterinary
• 7.3. Skin Infection
• 7.4. Respiratory Diseases
• 7.5. UTI and Pelvic Diseases
• 7.6. Others

8. AMINOGLYCOSIDES MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Shimadzu
• 10.2. Ringbio
• 10.3. Medscape
• 10.4. Fera Science
• 10.5. Sigma-Aldrich
• 10.6. Cipla Limited
• 10.7. Novartis AG
• 10.8. Vega Pharma Ltd
• 10.9. Insmed Corporation

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations